/

Sociétés

Zy

Non vérifié

Zymeworks Inc.

Ce que nous écrivons

Annonces ÉconomiquesBiotechnologieÉtablissements Publics/Vente au DétailFinanceMédecine Santé Bien-être

46 communiqués de presse

Voir tous les communiqués de presse

14/06/2026

Biotechnologie

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

Source

Émetteur

1.00

0

14/05/2026

Biotechnologie

Finance

Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock

Source

Émetteur

1.00

0

13/05/2026

Biotechnologie

Zymeworks Announces Participation in Upcoming Investor Conferences

Source

Émetteur

1.00

0

21/04/2026

Biotechnologie

Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026

Source

Émetteur

1.00

0

17/04/2026

Biotechnologie

Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform

Source

Émetteur

1.00

0

09/04/2026

Biotechnologie

Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth

Source

Émetteur

1.00

0

01/04/2026

Biotechnologie

Zymeworks Appoints Kristin Stafford as Chief Financial Officer

Source

Émetteur

1.00

0

30/03/2026

Biotechnologie

Annonces Économiques

Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRα-Targeting Antibody-Drug Conjugate

Source

Émetteur

1.00

0

18/03/2026

Biotechnologie

Zymeworks Announces Presentations for Ziihera® (zanidatamab-hrii) at 2026 AACR Annual Meeting

Source

Émetteur

1.00

0

17/03/2026

Biotechnologie

Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting

Source

Émetteur

1.00

0

Followers

0

Compatibilité

0